Strakonice

• An Open-Label Extension to Study the Long-Term Effect of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5) Under evaluation
  2024-510810-33-00 5 2024-10-14 Severe eosinophilic asthma
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Not authorised
  2023-503693-20-00 5 Severe eosinophilic asthma
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unex … Ended recruitment
  2024-513462-19-00 5 2023-03-30 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma
• A study comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF5993 With the Fixed Dose Dual Combination CHF153 … Ended
  2023-510172-31-00 5 2022-04-22 Chronic obstructive pulmonary disease (COPD)
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis

Showing 1–8 of 8 trials